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Dyslipidemia and progression of cardiovascular calcification
(CVC) in patients with end-stage renal disease (ESRD). Car-
diovascular calcification (CVC) is commonly encountered both
in the general population as well as in patients with end-
stage renal disease (ESRD). The etiology of CVC in patients
with ESRD is multifactorial. Despite that, current debate re-
mains narrowly focused on the role of calcium loading from
calcium-based phosphate binders (CBPB) in the pathogenesis
and progression of CVC. Yet, the alleged link between these
binders and CVC has not been substantiated in well-designed
controlled trials. In contrast, the purported role of sevelamer,
a non–calcium-based phosphate binder, in slowing the pro-
gression of CVC in dialysis patients has attracted widespread
attention. The beneficial effect of sevelamer on progression
of calcification was thought to be due to lower calcium
loading during its use. However, an alternative and possibly
more likely mechanism involves sevelamer-induced lowering
of LDL cholesterol. In this context, previous studies in indi-
viduals with normal renal function have documented amelio-
ration of coronary artery calcification (CAC) with reduction of
LDL-cholesterol by treatment with HMG-CoA reductase in-
hibitors (statins). Given that CAC is a well-accepted marker
of atherosclerosis, and that high plasma cholesterol concentra-
tion is one of the main risk factors for atherosclerosis, then it is
not unreasonable to suspect that CAC may be halted or even re-
versed by lowering of LDL cholesterol level with statin therapy.
Unfortunately, the effect of lowering the LDL-cholesterol level
on CAC has not been studied in patients with ESRD. Therefore,
conclusions about this important topic should await the results
of well-designed clinical studies that control for all factors po-
tentially implicated in the CVC burden of patients with ESRD.
In this review, I will discuss the role of various potential mech-
anisms involved in the pathogenesis of CVC in patients with
ESRD, and emphasize the role of dyslipidemia and its treat-
ment in this important clinical entity.
Cardiovascular disease is common and accounts for
at least 50% of deaths among ESRD patients [1]. Fo-
ley et al found that, compared to age- and sex-matched
individuals from the general population, dialysis patients
have a 2- to 100-fold greater risk of mortality, particularly
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the young [2]. The American Heart Association recently
issued a statement recommending that patients with
chronic kidney disease (CKD) be considered as mem-
bers of the ‘highest risk group’ for subsequent cardiovas-
cular disease events [3]. Similarly, the National Kidney
Foundation (NKF) Task Force on cardiovascular disease
(CVD) concluded that the incidence of atherosclerotic
CVD (ASCVD) is higher in patients with CKD com-
pared to the general population, and that patients with
CKD should be considered in the highest risk category
[i.e., a coronary heart disease (CHD) risk equivalent] for
the risk management [4].
High plasma levels of cholesterol, particularly low-
density lipoprotein (LDL) cholesterol, are established
risk factors for atherosclerosis. Strong evidence from
studies in the general population showed that dyslipi-
demia causes ASCVD. This conclusion has led to the
Adult Treatment Panel III (ATP III) guidelines for
evaluation and treatment of high blood cholesterol [5].
By contrast, there are no large, prospective studies exam-
ining the relationship between ASCVD and dyslipidemia
in ESRD patients. In a landmark study, Lindner et al
concluded that the high mortality rate in hemodialysis
patients was due to accelerated atherosclerosis [6].
Subsequently, retrospective, cross-sectional studies
found either no relationship or even a seemingly para-
doxic association between low serum cholesterol level
and increased mortality in hemodialysis patients [4].
In 1990, Lowrie and Lew reported that the association
between cholesterol and mortality in hemodialysis pa-
tients took the form of a U-shaped curve [7]. They noted
that the overall mortality risk was significantly higher
at lower total serum cholesterol levels in hemodialysis
patients [7]. This apparently paradoxic relationship
between serum cholesterol levels and mortality may, in
part, be explained by statistical adjustment for markers
of malnutrition and systemic inflammation [4]. Hence,
the correlation between low cholesterol and increased
mortality was reduced after adjusting for levels of serum
albumin [7, 8]. Other studies have shown that, in patients
with normal serum albumin, high serum cholesterol did
indeed predict mortality [9]. Recently, Liu et al showed
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Table 1. Risk factors for cardiovascular calcification in the general population and in CKD patients
Procalcification factors Uremia-related procalcification factors Anti-calcification factors
Older age Uremic serum Magnesium
Male sex Hyperphosphatemia Matrix GLA protein
Hypertension Increased Ca × P product Bone morphogenetic protein
Diabetes Exogenous Vitamin D therapy (BMP-7)
Smoking Elevated PTH levels Pyrophosphate
High LDL cholesterol Dialysis vintage Osteopontin
Low HDL cholesterol ?Calcium load and hypercalcemia Osteoprotegerin
Genetic predisposition Chronic inflammation PTHrP
Elevated leptin levels HDL
Decreased fetuin-A levels Fetuin-A
Treatment with warfarin Genetic factors
that the association between low total cholesterol level
and mortality in dialysis patients was likely due to the
cholesterol-lowering effect of systemic inflammation
and malnutrition, rather than a protective effect of high
cholesterol concentrations [10]. Thus, they concluded
that the results of their study support treatment of
hypercholesterolemia in dialysis patients. Unfortunately,
the beneficial effects of aggressive lowering of serum
lipid levels in patients with CKD have not yet been
well documented. Nonetheless, the treatment guidelines
adopted for adults with CKD by National Kidney
Foundation K/DOQI Work Group closely parallel those
recommended by ATP III guidelines [4].
CORONARY ARTERY CALCIUM IS A MARKER
FOR ATHEROSCLEROTIC CARDIOVASCULAR
DISEASE (ASCVD)
Because coronary artery disease (CAD) may be
asymptomatic, its prevalence in the general population,
as well as in patients with ESRD, is most likely underes-
timated. Approximately, 50% of myocardial infarctions
in the general population occur in patients with no prior
history of heart disease, and 68% of these infarctions are
due to lesions representing a diameter stenosis of less
than 50% [11]. Moreover, in up to 50% of cases of coro-
nary atherosclerosis, the initial manifestation of CAD
is sudden death or acute myocardial infarction [11–14].
Thus, early diagnosis remains an important goal in our
quest to reduce mortality from CAD. Unfortunately, con-
ventional risk factor assessment is neither sensitive nor
specific, and therefore, an alternative noninvasive quan-
titative approach to early diagnosis of coronary artery
atherosclerosis would be desirable.
Coronary artery calcium deposition is an integral part
of the atherosclerotic plaque, and CAC is a well-accepted
marker of atherosclerosis. Detection of calcification can
now be easily achieved with the newer imaging tech-
niques, such as electron-beam computed tomography
(EBCT) and spiral CT. These highly sensitive techniques
are being used with increasing frequency for screening
asymptomatic individuals at risk for developing coronary
artery disease [15]. As a result, studies have shown that
more than 90% of atherosclerotic plaques in the older
general population are calcified [16].
In the general population, coronary artery calcium
scores as measured by EBCT have generally been used
as an index of the atherosclerotic burden [16–18]. As
such, calcium scores correlate with histologic, intravascu-
lar ultrasound, and angiographic measurements of CAD
[19–21]. Furthermore, CAC score was found to be an
independent predictor of subsequent cardiac events in
both symptomatic and asymptomatic individuals [22–24].
Since the amount of calcium load in the coronary arter-
ies by EBCT reflects the total atherosclerotic plaque bur-
den, the use of EBCT offers the potential to evaluate
progression, stabilization, and even regression of calcifi-
cation through serial imaging.
PATHOGENESIS OF CARDIOVASCULAR
CALCIFICATION
In the last few years, strong evidence from experimen-
tal and genetic studies suggested that CVC is an active
and highly regulated process identical to bone formation
[25]. Indeed, fully formed bone, cartilage, and bone mar-
row elements were reported in the walls of blood vessels
[26].
Clinical and experimental studies have identified fac-
tors that promote calcification and others that inhibit cal-
cification (Table 1) [25]. Although each factor may play an
active role in CVC, it is believed that calcification of the
extracellular matrix occurs ‘by default,’ and that its inhi-
bition is the key active process [27]. This is not surprising
since we often encounter patients who have no evidence
of CVC despite having a number of risk factors known to
predispose to calcification. This suggests that inhibition
of calcification is genetically controlled, especially since
calcium-phosphate product in the extracellular fluids is
near the saturation point for mineral deposition [27]. On
the other hand, factors promoting calcification also play
an important role in CVC since they may transform cells
in the vessel wall into calcifying vascular cells. This is par-
ticularly true of vascular smooth muscle cells (VSMCs),
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which can adopt a calcifying phenotype in vitro. Vascu-
lar smooth muscle cells have been shown to resemble
osteoblasts in that they have the potential of express-
ing bone matrix and morphogenic proteins thought to be
involved in regulating normal osteogenesis, including os-
teopontin, osteonectin, matrix GLA protein, osteocalcin,
bone sialoprotein, and bone morphogenic protein 2a [28].
The demonstration that VSMCs express bone matrix pro-
teins supports the notion that vascular calcification is an
active, cell-mediated process.
THE ROLE OF HYPERLIPIDEMIA IN
PROGRESSION OF CAC
Previous studies have documented that the quantity
of coronary artery calcium as measured by computed to-
mography progresses over time [29–34]. Moreover, the
increase in coronary calcium during the follow-up period
is greater with higher baseline calcium scores [30, 32, 34].
Furthermore, in asymptomatic randomly selected indi-
viduals, CAC, once identified, progresses at a mean an-
nual rate of 24% when quantified by the Agatston score
[31].
Progression of CAC in the general population has been
linked to a number of traditional risk factors, such as age,
diabetes, hypertension, smoking, and hyperlipidemia. In
addition to these factors, patients with CKD are exposed
to uremia-related risk factors [25, 35].
Hyperlipidemia, particularly increased LDL, has been
implicated in progression of CAC. Schmermund et al re-
ported a mean annual progression of calcium scores in
symptomatic patients with normal renal function of 51%
and an association between LDL cholesterol levels and
the degree of progression of CAC [32]. Of the risk factors
studied, only LDL cholesterol levels were predictive of
progression of calcification.
Many studies have shown an association between
atherosclerotic calcification and lipid accumulation. In
cholesterol-fed rabbits and ApoE knockout mice, cal-
cification colocalizes with cholesterol crystals in the
intima [36, 37]. Moreover, microscopic calcification in
aortic valve forms in areas in which lipoproteins are
present [38], and early calcium deposits occur in and
around isolated VSMCs within the lipid core [39].
In order to understand the role of lipids in regulating
vascular calcification, it would be instructive to examine
their role in the mineralization of bone. Lipids are known
to play a role in both bone formation and bone resorption
[40]. They appear to be involved in early bone mineral-
ization at the level of nidus formation. The initial step in
hydroxyapatite crystal formation in bone involves the
generation of matrix vesicles, which act as nucleation
sites. These vesicles are membrane-bound structures that
bud off chondrocytes and osteoblasts. Matrix vesicles
contain phospholipids, phosphoproteins, and alkaline
phosphatase, which are thought to participate in the ini-
tiation of hydroxyapatite mineral formation [40]. Simi-
lar structures, probably derived from apoptotic VSMCs,
have been identified in human arteries [41]. Lipids have
been found within the extracellular matrix of bone nod-
ules formed in vitro [42]. In addition to matrix vesicles,
calcification also requires a receptive matrix. In calci-
fied atherosclerotic plaques, VSMCs express procalci-
fication proteins such as bone morphogenetic proteins,
bone sialoprotein, alkaline phosphatase, and others. The
presence of these proteins indicates a change in the phe-
notype of VSMCs into osteoblast-like cells. Biochemi-
cal studies have provided evidence that LDL cholesterol
can promote calcification of VSMCs, mainly due to lipid
peroxidation [43]. Proudfoot et al showed that lipid accu-
mulation occurs spontaneously in human VSMCs since
they express several lipoprotein and scavenger recep-
tors [44]. They also showed that modified lipoproteins
stimulate calcification by enhancing osteogenic differ-
entiation of these cells. This was substantiated by the
presence of cells exhibiting an osteogenic gene expression
profile within human atherosclerotic plaques [44]. Mod-
ified lipoproteins act via the scavenger receptor SRA 1
to inhibit VSMC phagocytosis of apoptotic bodies, thus
generating additional nidi for calcification [44]. Apop-
totic bodies have been shown to accumulate calcium and
calcify in vitro, suggesting that they may act as sites for
calcium crystal nucleation in atherosclerotic plaques [45,
46]. In view of the fact that lipids play a role in initiation
of hydroxyapatite formation, and that statins alter bone
remodeling, it is not surprising that lipid metabolism may
also influence the development of arterial calcification
[47, 48].
Serum LDL cholesterol is an established risk factor for
CAD and can, thus, be considered a surrogate marker
of atherosclerosis [49, 50]. Clinical studies have shown
that serum levels of LDL cholesterol are directly related
to the prevalence and extent of CAC as measured by
computed tomography, while levels of HDL cholesterol
were inversely related [15, 51, 52]. Atherosclerosis is a
purely inflammatory lesion that begins early in life as fatty
streaks. In individuals with hypercholesterolemia, the in-
flux of monocyte-derived macrophages and T lympho-
cytes is preceded by extracellular deposition of lipids [53].
Coronary artery calcification occurs when atherosclerosis
is present, and histologic studies have shown a close asso-
ciation between lipids and calcification in atherosclerotic
lesion [54, 55]. Since the coronary artery plaque is com-
posed of 20% calcium and 80% atherosclerosis, CAC is
considered a marker of coronary atherosclerosis [56, 57].
The actual mechanisms by which lipids play a role in
regulating vascular calcification is just beginning to un-
ravel. In 1994, Sarig et al demonstrated the presence
of cholesterol within the center of calcified granules of
atherosclerotic plaque using confocal microscopy, sug-
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gesting that cholesterol may act to nucleate the calcium
mineral crystals [58]. Moreover, 25-hydroxycholesterol, a
product of cholesterol oxidation found in atherosclerotic
lesions, has been shown to accelerate in vitro calcification
[59]. Finally, high tissue lipid content facilitates mineral-
ization in cholesterol-fed rabbits [60].
In 1994, Hoeg et al speculated that vascular calcifica-
tion relates to the duration and severity of exposure to
cholesterol [61]. They found that, in homozygous hyper-
lipidemic patients with documented records of choles-
terol levels, CAC scores by ultrafast CT was significantly
correlated with the cholesterol-year product. Later, Pohle
et al reported the rate of change in calcification as a func-
tion of change in lipid levels. They found that both CAC
and aortic valve calcification progress more rapidly in
patients with LDL levels greater than 130 mg/dL [62]. In
another study, LDL cholesterol correlated more strongly
with CAC than age, smoking, blood pressure, and fasting
insulin [63]. Moreover, LDL cholesterol was the only fac-
tor that correlated with the extent of progression of CAC
as measured by EBCT over an 18-month period [32].
EFFECT OF LOWERING THE LDL
CHOLESTEROL LEVELS ON PROGRESSION
OF CAC
The effect of lowering the LDL cholesterol levels on
progression of calcification has been reported by several
groups. In 299 symptomatic individuals who underwent
two consecutive EBCT scans at least 12 months apart,
Budoff et al observed a mean annual progression of CAC
of 33%. The group receiving statins demonstrated a pro-
gression rate of 15% compared with 39% for untreated
patients (P < 0.001). Indeed, among the 60 patients on
statin monotherapy, 37% had a decrease in the calcium
scores from baseline to follow-up scan [33]. In a retro-
spective study of asymptomatic individuals, Callister et
al demonstrated that treatment with HMG-CoA reduc-
tase inhibitors can reduce the volume of calcified plaque
in the coronary arteries (Fig. 1) [29]. At the follow-up
EBCT scans, a net reduction in the calcium-volume score
of 7% was observed only in treated patients whose final
LDL cholesterol levels were less than 120 mg/dL (P <
0.01). Untreated patients with an average LDL choles-
terol level of 147 mg/dL had a significant net increase in
mean calcium-volume score of 52% (P < 0.001). Even
treated patients whose LDL cholesterol levels remained
above 120 mg/dL had a mean annual progression of 25%.
Regression analysis of the percent change in the coro-
nary calcium-volume score in relation to the average LDL
cholesterol level in patients treated with HMG-CoA re-
ductase inhibitors for one year showed a linear relation-
ship (Fig. 2).
In the only prospective study on the effect of lipid-
lowering therapy on the progression of CAC, Achenbach
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Fig. 1. Reduction of LDL-cholesterol to less than 120 mg/dL resulted
in halting progression of CAC. In all groups, open bars represent ini-
tial values and closed bars the final values for coronary artery calcium-
volume scores. As can be seen, patients in group 1 who were not treated
with HMG-CoA reductase inhibitor had significant progression of coro-
nary calcification. Similarly, patients in group 2 who were also treated
but whose average LDL cholesterol levels remained above 120 mg/dL
had significant progression of calcification. Patients in group 3 who were
treated with HMG-CoA reductase inhibitor and whose average LDL
cholesterol levels were successfully reduced to less than 120 mg/dL had
no progression of calcification. Reproduced with permission from ref-
erence [29].
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Fig. 2. Regression analysis of the percent change in the coronary
calcium-volume score in relation to the average LDL cholesterol level
in patients treated with HMG-CoA reductase inhibitor for one year
showed a linear relationship. Reproduced with permission from refer-
ence [29].
et al found that treatment with the cholesterol-synthesis
enzyme inhibitor cerivastatin significantly reduced coro-
nary artery calcium progression in patients with LDL
cholesterol level greater than 130 mg/dL (Fig. 3) [64].
Cerivastatin therapy lowered the mean LDL cholesterol
level from 164 mg/dL to 107 mg/dL. The median annual
relative increase in coronary calcium was 25% during
the untreated period versus 8.8% during the treatment
period (P < 0.0001). Interestingly, in 32 patients with
an LDL cholesterol level <100 mg/dL under treatment,
the median annual relative change was 27% during the
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Fig. 3. (A) Reduction of progression of CAC during treatment with
a cholesterol-synthesis enzyme inhibitor cerivastatin. The figure shows
the annualized relative change of the calcium volume score during the
untreated period (EBT 1 to EBT 2), and during the treatment period
(EBT 2 to EBT 3), for all 66 patients. Despite interindividual variation,
the median annualized relative change (bold line) was significantly low-
ered by cerivastatin (25% vs. 8.8%, P < 0.0001). (B) Annualized rela-
tive change of the calcium volume score in 32 patients who achieved an
LDL cholesterol level <100 mg/dL during treatment with cerivastatin.
In these patients, the median annualized change (bold line) decreased
from 27% to −3.4% (P = 0.0001). Reproduced with permission from
reference [64].
untreated versus −3.4% during the treatment period
(P = 0.0001).
CARDIOVASCULAR CALCIFICATION IN
PATIENTS WITH ESRD
Coronary artery calcification is common in dialysis pa-
tients with ESRD. Previous studies have shown a number
of differences between CAC in the general population
and those with ESRD. First, the prevalence of cardiovas-
cular calcification, including CAC, valvular, and myocar-
dial calcification as detected by EBCT is clearly greater in
patients with ESRD than in the general population [65–
68]. Second, CAC appears at a much younger age group
in patients with ESRD [66]. Third, calcium scores as mea-
sured by EBCT are significantly higher in patients with
ESRD [65]. Moreover, the media thickness is increased,
and the coronary plaques are more heavily calcified, but
the size of the plaque itself is not increased in patients
with ESRD [69]. Fourth, progression of CAC over time
appears to be faster in patients with ESRD [65, 66]. Fifth,
the correlation between CAC and future development of
hard events is not as well established in ESRD patients.
Raggi et al reported the only study that showed a signifi-
cant correlation between CAC scores and atherosclerotic
cardiovascular disease events [70]. The lack of consistent
correlation between CAC scores in uremia and cardio-
vascular events may be due to a possible stabilizing effect
of heavy calcification, which may prevent rupture of the
atheromatous plaque, an event that is known to lead to
acute coronary syndrome. Indeed, Bonaficio et al recently
challenged the hypotheses that calcified atherosclerotic
plaques in uremia may create plaque instability and pro-
mote plaque rupture [71]. Finally, as discussed below,
the underlying pathophysiologic mechanisms for calci-
fication may also be different in patients with ESRD.
PATHOGENESIS OF CARDIOVASCULAR
CALCIFICATION IN ESRD PATIENTS
The mechanisms responsible for CVC in patients with
ESRD are still being debated, and have been previously
reviewed in detail [25]. Briefly, cross-sectional studies in
dialysis patients have shown a correlation between CAC
and a number of uremia-related factors, such as dialysis
vintage, hyperphosphatemia, high Ca × P product, and
vitamin D therapy [66–68]. Results from two observa-
tional studies found an association between vascular cal-
cification and the prescribed daily dose of calcium-based
phosphate binders (CBPB) [66, 67]. To investigate this
association further, Chertow et al conducted the Treat
to Goal Study, the first prospective randomized clinical
trial comparing progression of coronary and aortic cal-
cium scores obtained by EBCT in CBPB-treated patients
with those of sevelamer-treated patients [68]. They noted
a 25% increase in the coronary calcium scores among
the patients treated with calcium salts compared to a 6%
increment in the sevelamer group (P < 0.02). They con-
cluded that sevelamer was associated with amelioration
of coronary and aortic calcification, while CBPB may
lead to progression of calcification. Unfortunately, the
Treat to Goal Study suffers from a number of serious
design flaws, which clearly undermined its ability to sub-
stantiate the hypothesis that sevelamer, a non–calcium-
containing polymer, would be less likely to lead to pro-
gressive cardiovascular calcification than CBPB. First, in
order to test the hypothesis that calcium load from CBPB
is associated with progressive vascular calcification, the
protocol should not have allowed any supplemental cal-
cium in the sevelamer-treated patients. Unfortunately,
the sevelamer group was indeed provided additional cal-
cium supplements in the form of increased dialysate cal-
cium concentration to maintain normal serum calcium
level and increased vitamin D dose, which may have
led to enhanced intestinal calcium absorption. Moreover,
the protocol allowed sevelamer-treated patients to take
calcium supplement at bedtime on empty stomach to
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Table 2. Comparison of intestinal absorption of calcium from calcium CBPB and calcium supplement for prevention of hypocalcemia in
sevelamer-treated patients in the Treat to Goal Study
Supplemental calcium in
Calcium acetate Calcium carbonate sevelamer-treated patients
Dose mg/day 4600 mg with meals 3900 mg with meals 2250 mg on empty stomach
Elemental calcium content 25% 40%
1150 mg 1560 mg 900 mg
Calcium absorbed mg/day 26% 30% 39%
299 mg 468 mg 351 mg
correct hypocalcemia. Chertow et al had previously rec-
ommended that sevelamer-treated patients be given 900
mg elemental calcium at bedtime on empty stomach to
prevent hypocalcemia [72]. As illustrated in Table 2,
the estimated intestinal calcium absorption from calcium
supplement on empty stomach will be greater than that
absorbed when calcium acetate is taken with meals as
a phosphate binder. Therefore, data on calcium supple-
ment given to sevelamer-treated patients in the Treat to
Goal Study are essential in order to confirm that a signif-
icant difference in calcium loading did indeed exist be-
tween the sevelamer and CBPB-treatment arms. Since
the Treat to Goal Study did not control for the calcium
loading from nonbinder sources, it is impossible to as-
certain that patients treated with CBPB were actually
exposed to a higher calcium load than sevelamer-treated
group. Consequently, it becomes evident that the Treat to
Goal Study was not properly designed to provide defini-
tive conclusions about the role of calcium loading from
CBPB in progression of vascular calcification.
Second, a more likely explanation for the difference in
rate of progression of calcification in the Treat to Goal
Study may be the significant difference in LDL levels be-
tween the two treatment groups. In this context, patients
treated with sevelamer had a significant decrease in their
plasma LDL cholesterol levels from 102 to 65 mg/dL dur-
ing the study period, while the LDL levels did not change
in patients treated with CBPB. Since LDL level has been
previously shown to play an important role in coronary
artery calcification in the general population, the authors
of the Treat to Goal study should have controlled for
the LDL level in the two treatment groups. Lowering
the LDL by statin had been reported to ameliorate or
even reverse CAC in at least two previous studies [29,
64]. Given that the treat to goal study design did not al-
low for comparable lowering of the LDL levels in both
treatment groups, and that LDL was significantly lower in
sevelamer-treated patients, then it is possible that amelio-
ration of calcification in sevelamer-treated patients was
due to LDL-lowering effect. Sevelamer is a known anion
exchange resin and a bile acid sequestrant, which lowers
serum levels of LDL by 20% to 30% [73]. Therefore, it
is possible that the slower rate of progression of cardio-
vascular calcification observed in the Treat to Goal study
may have resulted from the significant lowering of the
LDL level by sevelamer. Similar opinions were recently
expressed by Goldsmith et al, who concluded that “the
Treat to Goal Study cannot inform us solely about the
role of oral calcium ingestion in the pathogenesis of car-
diovascular disease” [35]. Two other studies highlight the
role of dyslipidemia in the pathogenesis of CAC. Nitta
et al reported the results of their preliminary study from
Japan, which showed that progression of aortic calcifi-
cation in patients with ESRD was significantly retarded
during treatment with colistimide (a bile acid sequestrant
similar to sevelamer) in combination with atorvastatin
compared with the period before treatment was initiated
[74]. They speculated that the decrease in aortic calcifi-
cation was due to control of serum phosphorus and LDL
levels. Moreover, Tamashiro et al [75] reported that rapid
progression of CAC in hemodialysis patients was associ-
ated with higher triglycerides and lower HDL cholesterol
levels.
CONCLUSION
Cardiovascular calcification is very prevalent and often
severe in patients with ESRD. Its pathogenesis is likely
multifactorial. Recent emphasis on the role of calcium
load from the use of CBPB should not distract us from
examining the effects of other potential pathogenetic fac-
tors, such as hyperphosphatemia, the use of the large non-
physiologic doses of vitamin D, chronic inflammation, and
elevated LDL cholesterol. More widespread use of the
recently FDA approved cinacalcet HCl may prevent or
treat secondary hyperparathyroidism without increasing
serum calcium, phosphorus, or calcium-phosphorus prod-
uct, and may reduce the need for the use of large doses of
vitamin D sterols. On the other hand, the use of statins,
both for their lipid-lowering effect as well as their anti-
inflammatory effect, may prove useful in ameliorating or
even halting the progression of CVC. In order to more
carefully examine the relative contributions of calcium
loading from CBPB and lipid-lowering on cardiovascu-
lar calcification, we plan to conduct the Calcium Acetate
Renagel Evaluation-2 (CARE-2) Study, a prospective,
multicenter, randomized, open label, parallel arm, com-
parison of calcium acetate plus atorvastatin versus
sevelamer HCl with or without atorvastatin on CVC in
patients with ESRD. The treatment goal is to maintain
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serum phosphorus between 3.5 and 5.5 mg/dL as rec-
ommended by K/DOQI guidelines while reducing LDL
cholesterol levels in both groups to <70 mg/dL. The pri-
mary outcome measure will be the effect of this thera-
peutic intervention on progression of CVC as measured
by serial EBCT scanning at baseline and following one
year of treatment. Results of the CARE-2 Study should
be available in 2006.
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